Findings

What do systematic reviews say?

1,181 questions · 1,197 findings · 144 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 196 · 16.4%GRADE not reported 213 · 17.8%Very low 274 · 22.9%Low 296 · 24.7%Moderate 171 · 14.3%High 47 · 3.9%

PIMOZIDE vs carbamazepine

Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia

1 finding from 1 review

Non‐antiepileptic drugs for trigeminal neuralgia 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
GRADE not reported

Tizanidine vs carbamazepine

Reduction in pain intensity · patients with trigeminal neuralgia

The review found no eligible studies for this question.

1 finding from 1 review

Non‐antiepileptic drugs for trigeminal neuralgia 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tizanidine vs carbamazepine

Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia

The review found no eligible studies for this question.

1 finding from 1 review

Non‐antiepileptic drugs for trigeminal neuralgia 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tocainide vs carbamazepine

Reduction in pain intensity · patients with trigeminal neuralgia

The review found no eligible studies for this question.

1 finding from 1 review

Non‐antiepileptic drugs for trigeminal neuralgia 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tocainide vs carbamazepine

Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia

The review found no eligible studies for this question.

1 finding from 1 review

Non‐antiepileptic drugs for trigeminal neuralgia 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Appetite improvement compared to other drugs Questionnaire of appetite rating · cachexia anorexia syndrome

The intervention showed no clear difference in appetite improvement compared to other drugs Questionnaire of… (low certainty).

1 finding from 1 review

Megestrol acetate for treatment of anorexia‐cachexia syndrome 2013 · Cochrane Headline outcomes only
RR 1.03 [0.64, 1.67]
1 study · 475 participants
Low

Intervention not reported

Weight improvement compared to other drugs % of patients that improved their weight in kg · cachexia anorexia syndrome

It is very uncertain whether the intervention changes weight improvement compared to other drugs % of patients that… (very low certainty).

1 finding from 1 review

Megestrol acetate for treatment of anorexia‐cachexia syndrome 2013 · Cochrane Headline outcomes only
RR 1.66 [1.09, 2.52]
7 studies · 1131 participants
Very low

Intervention not reported

Retention to treatment Number of participants who competed treatment · Amphetamine abuse or dependence

The intervention showed no clear difference in retention to treatment Number of participants who competed treatment (low certainty).

1 finding from 1 review

Efficacy of psychostimulant drugs for amphetamine abuse or dependence 2013 · Cochrane Headline outcomes only
RR 1.01 [0.9, 1.14]
11 studies · 791 participants
Low

Intervention not reported

Serious drug related adverse events · Children aged less than 5 years

1 finding from 1 review

Intermittent preventive treatment for malaria in children living in areas with seasonal transmission 2012 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 9533 participants
Moderate

Itraconazole vs Fluconazole

Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
2 studies, 232 participants; effect not estimable
2 studies · 232 participants
GRADE not reported

Gabapentin vs placebo

50% or greater reduction in seizure frequency Number of seizures · people with drug‐resistant focal epilepsy

Gabapentin probably leads to higher reduction in seizure frequency of ≥ 50%: primary analysisNumber of… compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.89 [1.4, 2.55]
6 studies · 1206 participants
Moderate

Gabapentin vs placebo

Adverse effects: ataxia Number of participants experiencing ataxia · people with drug‐resistant focal epilepsy

Gabapentin may leads to higher adverse effects: ataxiaNumber of participants experiencing ataxia compared with placebo (low certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.01
3 studies · 787 participants
Low

Gabapentin vs placebo

Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy

Gabapentin probably leads to higher adverse effects: dizzinessNumber of participants experiencing… compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.43
6 studies · 1206 participants
Moderate

Gabapentin vs placebo

Adverse effect: fatigue · people with drug‐resistant focal epilepsy

Gabapentin may leads to higher adverse effects: fatigueNumber of participants experiencing fatigue compared with placebo (low certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.95
5 studies · 1161 participants
Low

Gabapentin vs placebo

Nausea · people with drug‐resistant focal epilepsy

Gabapentin probably leads to lower adverse effects: nauseaNumber of participants experiencing nausea compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 0.95
4 studies · 1034 participants
Moderate

Gabapentin vs placebo

Somnolence · people with drug‐resistant focal epilepsy

Gabapentin probably leads to higher adverse effects: somnolenceNumber of participants experiencing… compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.93
6 studies · 1206 participants
Moderate

Gabapentin vs placebo

Adverse effects: headache · people with drug‐resistant focal epilepsy

Gabapentin probably leads to lower adverse effects: headacheNumber of participants experiencing headache compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 0.79
6 studies · 1206 participants
Moderate

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
RR 3.56 [2.37, 5.37]
3 studies · 2265 participants
Moderate

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
RR 1.02 [0.58, 1.77]
2 studies · 1993 participants
Moderate

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
RR 1.06 [0.65, 1.75]
3 studies · 2760 participants
Moderate